Karlin Nina J, Kosiorek Heidi E, Verona Patricia M, Coppola Kyle E, Cook Curtiss B
Division of Hematology & Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA.
Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona, USA.
Future Sci OA. 2023 Jan 9;8(9):FSO820. doi: 10.2144/fsoa-2022-0018. eCollection 2022 Oct.
To determine overall survival (OS) and glycemic control in patients with cancer and diabetes.
MATERIALS & METHODS: Patients of our institution with breast, colon, lung, pancreas and prostate cancer were retrospectively reviewed. OS was compared between matched patients with and without diabetes, and changes in glucose value over time were assessed.
For 3934 patients each with and without diabetes, adjusted analysis showed no difference in OS according to diabetes status (hazard ratio: 1.07; 95% CI: 0.96-1.20). Mean glucose values decreased over time in patients with and without diabetes (p = 0.01).
In this large study of patients with five common cancers, the co-occurrence of diabetes did not affect OS. Cancer did not adversely affect glucose levels.
确定癌症合并糖尿病患者的总生存期（OS）和血糖控制情况。
对本机构患有乳腺癌、结肠癌、肺癌、胰腺癌和前列腺癌的患者进行回顾性研究。比较配对的糖尿病患者和非糖尿病患者的总生存期，并评估血糖值随时间的变化。
对于3934例糖尿病患者和非糖尿病患者，校正分析显示糖尿病状态对总生存期无差异（风险比：1.07；95%置信区间：0.96-1.20）。糖尿病患者和非糖尿病患者的平均血糖值均随时间下降（p = 0.01）。
在这项对五种常见癌症患者的大型研究中，糖尿病的并存不影响总生存期。癌症对血糖水平没有不利影响。
